Excellent. Below are full, detailed model answers in standard MBBS pharmacology style (mechanism, rationale, regimen, adverse effects, and key clinical points), written so you can reproduce in exams.
Q-1 (A) Structured long questions
1) Severe postoperative pain treated with morphine
Explain mechanism of action and pharmacological actions of morphine poisoning.
(In many university papers, the wording means: explain MOA + clinical/pharmacological manifestations of morphine toxicity/poisoning.)
A. Mechanism of action of morphine
Morphine is a strong opioid agonist, predominantly at mu (μ) receptors (also weak activity at κ and δ).
Receptor and signaling
- Opioid receptors are Gi/Go-coupled GPCRs.
- On activation:
- ↓ Adenylyl cyclase activity → ↓ cAMP
- Closes presynaptic voltage-gated Ca²⁺ channels → less release of substance P, glutamate, CGRP
- Opens postsynaptic K⁺ channels → hyperpolarization and reduced neuronal firing
Net effect
- Inhibition of nociceptive neurotransmission in:
- dorsal horn of spinal cord
- ascending pain pathways
- supraspinal pain-modulating circuits
- Also changes emotional perception of pain (limbic system effect).
B. Pharmacological actions (normal therapeutic profile)
-
CNS
- Powerful analgesia (somatic and visceral)
- Sedation, mental clouding
- Euphoria (sometimes dysphoria)
- Antitussive action at medullary cough center
- Miosis (pinpoint pupil) via Edinger-Westphal nucleus
- Respiratory depression (↓ sensitivity to CO₂)
-
GIT
- ↓ Propulsive motility, ↑ segmenting contractions
- Delayed gastric emptying
- Constipation
-
Biliary and smooth muscle
- Spasm of sphincter of Oddi (biliary colic may worsen)
- Urinary retention (↑ sphincter tone)
-
CVS
- Usually mild effects at therapeutic dose
- Peripheral vasodilation (histamine release), possible postural hypotension
-
Endocrine/other
- Nausea, vomiting (CTZ stimulation)
- Pruritus/flushing due to histamine
C. Morphine poisoning (opioid overdose): clinical features
Classic triad
- Coma / profound CNS depression
- Pinpoint pupils (miosis)
- may become mid-dilated in terminal hypoxia
- Respiratory depression (most dangerous; can cause death)
Other signs
- Slow, shallow breathing, cyanosis
- Bradycardia, hypotension
- Hypothermia
- Reduced bowel sounds, urinary retention
- Pulmonary edema in severe poisoning
D. Management of morphine poisoning
-
Airway, breathing, circulation first
- Maintain airway, oxygen, assisted ventilation if needed
-
Specific antidote: Naloxone
- Competitive opioid antagonist (high affinity for μ receptors)
- IV bolus, repeated or infusion (because naloxone duration < some opioids)
-
Supportive care
- Fluids/vasopressor if hypotension
- Monitor ABG, ECG, SpO₂
- Observe for renarcotization
-
In dependence, naloxone may precipitate withdrawal; still life-saving in overdose.
2) Newly diagnosed pulmonary tuberculosis
Describe treatment regimen. Key points while treating TB. What is MDR-TB?
A. Standard treatment regimen for drug-susceptible new pulmonary TB
Current standard (programmatic/WHO-aligned principle): 6-month regimen
- Intensive phase (2 months):
H + R + Z + E
(Isoniazid, Rifampicin, Pyrazinamide, Ethambutol)
- Continuation phase (4 months):
H + R
Mnemonic: 2HRZE / 4HR
Usually given as daily fixed-dose combinations, weight-based dosing.
B. First-line anti-TB drugs and key role
- Isoniazid (H): potent early bactericidal drug
- Rifampicin (R): sterilizing drug; prevents relapse
- Pyrazinamide (Z): active in acidic intracellular sites; shortens therapy
- Ethambutol (E): protects against resistance when susceptibility unknown
C. Key points to consider in TB treatment
- Never use monotherapy for active TB.
- Adherence is critical
- DOT/adherence support, counseling
- Use correct weight-based doses
- Baseline evaluation
- LFT, renal function if indicated
- HIV status, diabetes screening
- Pregnancy status, vision exam when prolonged ethambutol risk
- Monitor adverse effects
- H: hepatitis, peripheral neuropathy (give pyridoxine in risk groups)
- R: hepatitis, orange discoloration, drug interactions (enzyme inducer)
- Z: hepatotoxicity, hyperuricemia
- E: optic neuritis (red-green color vision)
- Check sputum/microbiological response per protocol
- Contact tracing and infection control
- Comorbidities
- HIV co-treatment and ART timing
- diabetes control, nutrition
- Avoid treatment interruption, because it promotes failure/relapse/resistance.
- Drug susceptibility testing (DST) should guide modifications if non-response/resistance.
D. What is MDR-TB?
MDR-TB (Multidrug-resistant TB) = TB caused by Mycobacterium tuberculosis resistant to at least:
- Isoniazid (H) and
- Rifampicin (R)
(with or without resistance to other drugs).
Clinical significance:
- Requires longer, more toxic, costlier second-line regimens.
- Managed with DST-guided all-oral regimens (commonly including agents like bedaquiline, linezolid, fluoroquinolones etc., as per national/WHO protocol).
Q-2 (B) Attempt any TWO (detailed answers for all three)
1) Case suggestive of enteric fever; widal positive for Salmonella typhi
a) Drugs with duration
b) Mechanism of action and adverse effects (any one drug)
A. Drugs used for typhoid fever (uncomplicated, susceptibility-guided)
Common options (regional resistance pattern matters):
- Ceftriaxone (parenteral, severe/hospitalized cases)
- Cefixime (oral in selected uncomplicated cases)
- Azithromycin (oral; useful where quinolone resistance high)
- Fluoroquinolones (ciprofloxacin/ofloxacin) only if proven susceptible
Typical durations (exam-friendly)
- Azithromycin: 5–7 days
- Cefixime: 10–14 days
- Ceftriaxone: 10–14 days (or per clinical response)
- Ciprofloxacin: 7–10 days if organism susceptible
(Always tailor to culture/sensitivity and local guidelines.)
B. One drug in detail (example: Ceftriaxone)
Mechanism of action
- Third-generation cephalosporin (β-lactam)
- Binds penicillin-binding proteins (PBPs)
- Inhibits transpeptidation of peptidoglycan → defective bacterial cell wall synthesis
- Bactericidal
Adverse effects
- Hypersensitivity rash, anaphylaxis (rare)
- Diarrhea, nausea
- Biliary sludge/pseudolithiasis (especially children, high dose)
- Injection site pain
- Rare: C. difficile colitis, hematologic changes
(If exam asks any one drug, azithromycin or ciprofloxacin can also be written similarly.)
2) 8-year-old with ODD + momentary loss of consciousness, staring, eyelid flutter
(typical absence seizures)
a) Drug of choice and suitable alternatives with mechanism
b) Lifelong treatment needed?
A. Diagnosis pattern
- Brief staring spells, eyelid blinking, sudden onset/offset, minimal postictal confusion
- Typical of absence seizures (petit mal)
B. Drug of choice (DOC)
Ethosuximide
Mechanism
- Selective blockade of T-type Ca²⁺ channels in thalamic neurons
- Suppresses thalamocortical 3-Hz spike-wave discharges
- Highly effective for pure absence seizures
Adverse effects
- GI upset, anorexia
- Drowsiness, fatigue, headache
- Behavioral changes
- Rare blood dyscrasias, rash
C. Suitable alternatives
-
Valproate (sodium valproate)
- Preferred if mixed seizure types (absence + generalized tonic-clonic)
- MOA: ↑ GABA (inhibits GABA metabolism), blocks Na⁺ channels, reduces T-type Ca²⁺ currents
-
Lamotrigine
- Less effective than ethosuximide/valproate for pure absence but useful alternative
- MOA: blocks voltage-gated Na⁺ channels, reduces glutamate release
D. Is lifelong treatment needed?
Usually no.
- Childhood absence epilepsy often has good prognosis.
- Continue treatment for seizure control; reassess after prolonged seizure-free period (commonly about 2 years seizure-free, plus EEG/clinical judgment).
- Gradual taper may be attempted under specialist supervision.
- A subset may persist/convert; hence individualized follow-up is required.
3) 27-year-old female with uncomplicated UTI; pregnant
a) Suitable drug with mechanism
b) Two antimicrobials contraindicated/avoided in pregnancy for UTI with justification
A. Suitable drug in pregnancy (example)
Nitrofurantoin (for uncomplicated cystitis; avoid near term)
Mechanism
- Reduced by bacterial flavoproteins to reactive intermediates
- Damages bacterial DNA/ribosomal proteins and metabolic enzymes
- Concentrates in urine; effective in lower UTI
Notes
- Good for lower UTI, not pyelonephritis
- Avoid at term (risk hemolysis in G6PD-deficient newborn)
(Alternative pregnancy-safe options often include amoxicillin-clavulanate, cephalexin, fosfomycin depending on sensitivity.)
B. Two drugs avoided/contraindicated (with reasons)
-
Fluoroquinolones (e.g., ciprofloxacin)
- Avoid in pregnancy due to concern for fetal cartilage/joint toxicity (animal data) and safer alternatives available.
-
Tetracyclines (e.g., doxycycline)
- Contraindicated: deposition in fetal bone/teeth, tooth discoloration, inhibition of bone growth, maternal hepatotoxicity risk.
(Also often avoided in late pregnancy: TMP-SMX near term due to kernicterus risk and folate effects in early pregnancy.)
Q-3 Write short notes on ANY THREE (all four given)
1) Therapeutic uses and adverse effects of Metronidazole
Therapeutic uses
- Protozoal infections:
- Amoebiasis (intestinal and hepatic)
- Giardiasis
- Trichomoniasis (treat sexual partners too)
- Anaerobic bacterial infections:
- Intra-abdominal, pelvic, dental anaerobic infections
- Brain abscess (anaerobic component)
- C. difficile infection (historically; now alternatives often preferred in many guidelines)
- Part of H. pylori eradication regimens
- Bacterial vaginosis
- Surgical prophylaxis for anaerobic contamination (e.g., colorectal)
Mechanism (brief)
- Nitro group reduced in anaerobes/protozoa to cytotoxic radicals
- Causes DNA strand breaks and inhibits nucleic acid synthesis
- Bactericidal/protozoacidal
Adverse effects
- Metallic taste, nausea, abdominal discomfort
- Headache, dizziness
- Dark urine
- Peripheral neuropathy (prolonged use)
- Disulfiram-like reaction with alcohol (avoid alcohol during and at least 48–72 h after course)
- Rare CNS toxicity, leukopenia
2) Compare benzodiazepines vs non-benzodiazepine hypnotics
| Feature | Benzodiazepines (e.g., diazepam, lorazepam, nitrazepam) | Non-benzodiazepine Z-drugs (zolpidem, zopiclone, zaleplon) |
|---|
| Receptor action | GABA-A positive allosteric modulators at BZD site; broader subunit action | Also act at BZD site but relatively selective for α1-containing GABA-A (hypnotic) |
| Main effects | Anxiolytic, sedative-hypnotic, muscle relaxant, anticonvulsant | Predominantly hypnotic (sleep induction) |
| Sleep architecture | Can reduce slow-wave sleep; REM effects variable | Less disruption of sleep architecture (generally) |
| Daytime sedation | More likely (especially long-acting drugs) | Usually less next-day sedation (agent/dose dependent) |
| Dependence/tolerance | Present; withdrawal possible | Also present, but generally somewhat lower risk at short-term use |
| Anterograde amnesia | Can occur | Can occur (e.g., complex sleep behaviors with zolpidem) |
| Use | Anxiety, status epilepticus, muscle spasm, insomnia | Mainly short-term insomnia |
| Overdose | Safer than barbiturates; severe CNS depression with alcohol/opioids | Similar caution; additive CNS depression with alcohol/sedatives |
Exam conclusion: Z-drugs are preferred for short-term insomnia when daytime anxiolysis/muscle relaxation is not needed.
3) “Justice” as a bioethical principle in healthcare
Justice means fairness in distribution of healthcare resources, risks, costs, and benefits.
Components
- Distributive justice
- Fair allocation of ICU beds, dialysis slots, organs, vaccines, medicines.
- Procedural justice
- Transparent, consistent, impartial decision-making.
- Social justice
- Attention to vulnerable groups; reducing inequities by class, gender, caste, geography, disability.
In clinical practice
- Similar patients should be treated similarly.
- No discrimination on non-medical grounds.
- Triage should be need- and benefit-based.
- Rational prescribing: avoid unnecessary expensive therapy when equivalent cheaper options exist.
- Public health ethics: balancing individual autonomy and population welfare.
Relevance to pharmacology
- Essential medicines list and generic prescribing
- Cost-effectiveness and rational use
- Equitable access to life-saving drugs
4) Selective serotonin reuptake inhibitors (SSRIs)
Drugs
- Fluoxetine, sertraline, paroxetine, citalopram, escitalopram, fluvoxamine
Mechanism
- Selective inhibition of serotonin transporter (SERT) at presynaptic terminal
- ↑ 5-HT in synaptic cleft
- Minimal direct effect on NE/DA reuptake compared to TCAs
Indications
- Major depressive disorder
- Anxiety disorders (GAD, panic disorder, social anxiety)
- OCD
- PTSD
- PMDD
- Bulimia nervosa (fluoxetine)
Adverse effects
- GI upset, nausea, diarrhea
- Insomnia or somnolence
- Sexual dysfunction (decreased libido, delayed ejaculation, anorgasmia)
- Initial anxiety/agitation in some patients
- Weight changes (variable)
- Hyponatremia/SIADH (elderly)
- Increased bleeding tendency (platelet serotonin depletion), especially with NSAIDs/anticoagulants
- Serotonin syndrome (with MAOIs, linezolid, tramadol, triptans etc.)
- Discontinuation syndrome (notably paroxetine)
- QT prolongation risk with high-dose citalopram
Important precautions
- Avoid with MAO inhibitors (washout required)
- Monitor suicidal risk in adolescents/young adults early in treatment
- Pregnancy: individualized risk-benefit assessment
Advantages over TCAs
- Better safety in overdose
- Fewer anticholinergic and cardiotoxic effects
- Better tolerability overall
If you want, I can now convert this into a clean exam-writing format (with exact heading style, underlining points, and mnemonic lines) so you can directly memorize and reproduce in university answers.